X

Drug Profile

Research programme: vaccines - Nykode Therapeutics/Regeneron Pharmaceuticals

Latest Information Update: 08 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regeneron Pharmaceuticals; Vaccibody
Developer Nykode Therapeutics; Regeneron Pharmaceuticals
Class Anti-infectives; Antineoplastics; Cancer vaccines; DNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Cancer; Infections

Most Recent Events

23 Nov 2021 Vaccibody is now called Nykode Therapeutics
23 Nov 2021 Nykode Therapeutics (Vaccibody) and Regeneron Pharmaceuticals agree to co-promote and co-develop vaccines for cancer and infectious disease
23 Nov 2021 Early research in Cancer in USA and Norway (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com